Cartesian Therapeutics, Inc.RNAC
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · cartesiantherapeutics.com
Cartesian Therapeutics is a clinical-stage biotechnology company developing mRNA-based cell therapies for autoimmune disease, led by Descartes-08, an autologous mRNA CAR-T candidate for myasthenia gravis.
Key ratios
FCF / Sales
-5322.5%TTM
2025
-2838.6%2024
-84.2%2023
-197.5%
Net margin
-112.1%TTM
2024
-199.0%
ROA
-17.4%TTM
2025
-14.8%2024
-6.0%2023
-19.8%
Revenue growth
44.0%TTM
2025
-92.8%2024
49.6%2023
-76.5%
Track RNAC in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer